Sebelipase alfa

Sebelipase alfa
Clinical data
Trade names	Kanuma
AHFS/Drugs.com	Monograph
License data	US DailyMed: Sebelipase_alfa;
Pregnancy; category	AU: B1;
Routes of; administration	Intravenous infusion
ATC code	A16AB14 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	0.1 hours
Identifiers
CAS Number	1276027-63-4;
DrugBank	DB11563;
ChemSpider	none;
UNII	K4YTU42T8G;
KEGG	D10377;

Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015.